Loading…
21 Inhibiting PARP-1 to restore temozolomide sensitivity and prevent resistance in glioblastoma
Adult Glioblastomas (GBMs) remain one of the least curable brain cancers despite the discovery and use of DNA alkylating agent Temozolomide (TMZ). TMZ provides a moderate survival benefit to sensitive patients whose O6-methylguanine-methyltransferase (MGMT) gene is silenced by promoter methylation....
Saved in:
Published in: | Canadian journal of neurological sciences 2018-06, Vol.45 (S3), p.S4-S4 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c1859-d2ccf1153a2993f84f5c5940cd72a8046076995b2ab1950602480228d968173f3 |
---|---|
cites | |
container_end_page | S4 |
container_issue | S3 |
container_start_page | S4 |
container_title | Canadian journal of neurological sciences |
container_volume | 45 |
creator | Bering, E. A. Yuan, A. L. Cairncross, J. G. Blough, M. D. |
description | Adult Glioblastomas (GBMs) remain one of the least curable brain cancers despite the discovery and use of DNA alkylating agent Temozolomide (TMZ). TMZ provides a moderate survival benefit to sensitive patients whose O6-methylguanine-methyltransferase (MGMT) gene is silenced by promoter methylation. Unfortunately, TMZ potential is stunted because of the rapid onset of tumour recurrence and acquired resistance believed to result from the upregulation of DNA damage repair by the base excision repair (BER), mismatch repair (MMR), or homologous recombination (HR) systems. Our laboratory previously demonstrated that cell lines obtained from recurrent, TMZ-resistant GBMs could be re-sensitized to TMZ when treated with an inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1) – a protein instrumental in the recruitment of BER machinery. From this preliminary research, we postulate that PARP-1 inhibition may not only be used to overcome established resistance in GBM but may also be used to prevent its emergence altogether. To test this hypothesis, we utilized the MGMT-methylated GBM cell line U251N and developed an in vitro model of inducible TMZ resistance. We verified that prolonged treatment of U251N cells with TMZ resulted in the emergence of resistant colonies that resembled recurrent GBM clinically observed in TMZ-treated patients. However, when the parental U251N line was co-treated with TMZ and PARP-1 inhibitor ABT-888, resistant colonies failed to appear. Therefore, PARP-1 inhibition may possess the potential to maintain tumour sensitivity to TMZ as well as evade the otherwise inevitable development of resistance in GBM. |
doi_str_mv | 10.1017/cjn.2018.309 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2799854388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_cjn_2018_309</cupid><sourcerecordid>2799854388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1859-d2ccf1153a2993f84f5c5940cd72a8046076995b2ab1950602480228d968173f3</originalsourceid><addsrcrecordid>eNptkM9LwzAYhoMoOKc3_4CAV1u_pE2THMfwx2DgED2HNE1nRpvMpBvMv94OB148fZfnfd-PB6FbAjkBwh_MxucUiMgLkGdoQoHxDAhj52gCBeEZqTi5RFcpbQBoxapyghQleOE_Xe0G59d4NXtbZQQPAUebhhAtHmwfvkMXetdYnKxPI7h3wwFr3-BttHvrhyPs0qC9sdh5vO5cqDs95nt9jS5a3SV7c7pT9PH0-D5_yZavz4v5bJkZIpjMGmpMSwgrNJWyaEXZMsNkCabhVAsoK-CVlKymuiaSQQW0FECpaGQlCC_aYorufnu3MXztxt_VJuyiHycV5VIKVhZCjNT9L2ViSCnaVm2j63U8KALqqFCNCtVRoRoVjnh-wnVfR9es7V_rv4EfiahyHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2799854388</pqid></control><display><type>article</type><title>21 Inhibiting PARP-1 to restore temozolomide sensitivity and prevent resistance in glioblastoma</title><source>Cambridge University Press</source><creator>Bering, E. A. ; Yuan, A. L. ; Cairncross, J. G. ; Blough, M. D.</creator><creatorcontrib>Bering, E. A. ; Yuan, A. L. ; Cairncross, J. G. ; Blough, M. D.</creatorcontrib><description>Adult Glioblastomas (GBMs) remain one of the least curable brain cancers despite the discovery and use of DNA alkylating agent Temozolomide (TMZ). TMZ provides a moderate survival benefit to sensitive patients whose O6-methylguanine-methyltransferase (MGMT) gene is silenced by promoter methylation. Unfortunately, TMZ potential is stunted because of the rapid onset of tumour recurrence and acquired resistance believed to result from the upregulation of DNA damage repair by the base excision repair (BER), mismatch repair (MMR), or homologous recombination (HR) systems. Our laboratory previously demonstrated that cell lines obtained from recurrent, TMZ-resistant GBMs could be re-sensitized to TMZ when treated with an inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1) – a protein instrumental in the recruitment of BER machinery. From this preliminary research, we postulate that PARP-1 inhibition may not only be used to overcome established resistance in GBM but may also be used to prevent its emergence altogether. To test this hypothesis, we utilized the MGMT-methylated GBM cell line U251N and developed an in vitro model of inducible TMZ resistance. We verified that prolonged treatment of U251N cells with TMZ resulted in the emergence of resistant colonies that resembled recurrent GBM clinically observed in TMZ-treated patients. However, when the parental U251N line was co-treated with TMZ and PARP-1 inhibitor ABT-888, resistant colonies failed to appear. Therefore, PARP-1 inhibition may possess the potential to maintain tumour sensitivity to TMZ as well as evade the otherwise inevitable development of resistance in GBM.</description><identifier>ISSN: 0317-1671</identifier><identifier>EISSN: 2057-0155</identifier><identifier>DOI: 10.1017/cjn.2018.309</identifier><language>eng</language><publisher>New York, USA: Cambridge University Press</publisher><subject>10 MAY 2018 @ 1800-1900: 11 MAY 2018 @ 1620-1720: 12 MAY 2018 @ 1010-1035 ; Apoptosis ; Autophagy ; Brain cancer ; DNA methylation ; DNA repair ; Medical prognosis ; Mutation ; POSTER VIEWING SESSIONS ; Radiation</subject><ispartof>Canadian journal of neurological sciences, 2018-06, Vol.45 (S3), p.S4-S4</ispartof><rights>The Canadian Journal of Neurological Sciences Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1859-d2ccf1153a2993f84f5c5940cd72a8046076995b2ab1950602480228d968173f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S0317167118003098/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,72960</link.rule.ids></links><search><creatorcontrib>Bering, E. A.</creatorcontrib><creatorcontrib>Yuan, A. L.</creatorcontrib><creatorcontrib>Cairncross, J. G.</creatorcontrib><creatorcontrib>Blough, M. D.</creatorcontrib><title>21 Inhibiting PARP-1 to restore temozolomide sensitivity and prevent resistance in glioblastoma</title><title>Canadian journal of neurological sciences</title><addtitle>Can. J. Neurol. Sci</addtitle><description>Adult Glioblastomas (GBMs) remain one of the least curable brain cancers despite the discovery and use of DNA alkylating agent Temozolomide (TMZ). TMZ provides a moderate survival benefit to sensitive patients whose O6-methylguanine-methyltransferase (MGMT) gene is silenced by promoter methylation. Unfortunately, TMZ potential is stunted because of the rapid onset of tumour recurrence and acquired resistance believed to result from the upregulation of DNA damage repair by the base excision repair (BER), mismatch repair (MMR), or homologous recombination (HR) systems. Our laboratory previously demonstrated that cell lines obtained from recurrent, TMZ-resistant GBMs could be re-sensitized to TMZ when treated with an inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1) – a protein instrumental in the recruitment of BER machinery. From this preliminary research, we postulate that PARP-1 inhibition may not only be used to overcome established resistance in GBM but may also be used to prevent its emergence altogether. To test this hypothesis, we utilized the MGMT-methylated GBM cell line U251N and developed an in vitro model of inducible TMZ resistance. We verified that prolonged treatment of U251N cells with TMZ resulted in the emergence of resistant colonies that resembled recurrent GBM clinically observed in TMZ-treated patients. However, when the parental U251N line was co-treated with TMZ and PARP-1 inhibitor ABT-888, resistant colonies failed to appear. Therefore, PARP-1 inhibition may possess the potential to maintain tumour sensitivity to TMZ as well as evade the otherwise inevitable development of resistance in GBM.</description><subject>10 MAY 2018 @ 1800-1900: 11 MAY 2018 @ 1620-1720: 12 MAY 2018 @ 1010-1035</subject><subject>Apoptosis</subject><subject>Autophagy</subject><subject>Brain cancer</subject><subject>DNA methylation</subject><subject>DNA repair</subject><subject>Medical prognosis</subject><subject>Mutation</subject><subject>POSTER VIEWING SESSIONS</subject><subject>Radiation</subject><issn>0317-1671</issn><issn>2057-0155</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNptkM9LwzAYhoMoOKc3_4CAV1u_pE2THMfwx2DgED2HNE1nRpvMpBvMv94OB148fZfnfd-PB6FbAjkBwh_MxucUiMgLkGdoQoHxDAhj52gCBeEZqTi5RFcpbQBoxapyghQleOE_Xe0G59d4NXtbZQQPAUebhhAtHmwfvkMXetdYnKxPI7h3wwFr3-BttHvrhyPs0qC9sdh5vO5cqDs95nt9jS5a3SV7c7pT9PH0-D5_yZavz4v5bJkZIpjMGmpMSwgrNJWyaEXZMsNkCabhVAsoK-CVlKymuiaSQQW0FECpaGQlCC_aYorufnu3MXztxt_VJuyiHycV5VIKVhZCjNT9L2ViSCnaVm2j63U8KALqqFCNCtVRoRoVjnh-wnVfR9es7V_rv4EfiahyHg</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Bering, E. A.</creator><creator>Yuan, A. L.</creator><creator>Cairncross, J. G.</creator><creator>Blough, M. D.</creator><general>Cambridge University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>201806</creationdate><title>21 Inhibiting PARP-1 to restore temozolomide sensitivity and prevent resistance in glioblastoma</title><author>Bering, E. A. ; Yuan, A. L. ; Cairncross, J. G. ; Blough, M. D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1859-d2ccf1153a2993f84f5c5940cd72a8046076995b2ab1950602480228d968173f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>10 MAY 2018 @ 1800-1900: 11 MAY 2018 @ 1620-1720: 12 MAY 2018 @ 1010-1035</topic><topic>Apoptosis</topic><topic>Autophagy</topic><topic>Brain cancer</topic><topic>DNA methylation</topic><topic>DNA repair</topic><topic>Medical prognosis</topic><topic>Mutation</topic><topic>POSTER VIEWING SESSIONS</topic><topic>Radiation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bering, E. A.</creatorcontrib><creatorcontrib>Yuan, A. L.</creatorcontrib><creatorcontrib>Cairncross, J. G.</creatorcontrib><creatorcontrib>Blough, M. D.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Canadian journal of neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bering, E. A.</au><au>Yuan, A. L.</au><au>Cairncross, J. G.</au><au>Blough, M. D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>21 Inhibiting PARP-1 to restore temozolomide sensitivity and prevent resistance in glioblastoma</atitle><jtitle>Canadian journal of neurological sciences</jtitle><addtitle>Can. J. Neurol. Sci</addtitle><date>2018-06</date><risdate>2018</risdate><volume>45</volume><issue>S3</issue><spage>S4</spage><epage>S4</epage><pages>S4-S4</pages><issn>0317-1671</issn><eissn>2057-0155</eissn><abstract>Adult Glioblastomas (GBMs) remain one of the least curable brain cancers despite the discovery and use of DNA alkylating agent Temozolomide (TMZ). TMZ provides a moderate survival benefit to sensitive patients whose O6-methylguanine-methyltransferase (MGMT) gene is silenced by promoter methylation. Unfortunately, TMZ potential is stunted because of the rapid onset of tumour recurrence and acquired resistance believed to result from the upregulation of DNA damage repair by the base excision repair (BER), mismatch repair (MMR), or homologous recombination (HR) systems. Our laboratory previously demonstrated that cell lines obtained from recurrent, TMZ-resistant GBMs could be re-sensitized to TMZ when treated with an inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1) – a protein instrumental in the recruitment of BER machinery. From this preliminary research, we postulate that PARP-1 inhibition may not only be used to overcome established resistance in GBM but may also be used to prevent its emergence altogether. To test this hypothesis, we utilized the MGMT-methylated GBM cell line U251N and developed an in vitro model of inducible TMZ resistance. We verified that prolonged treatment of U251N cells with TMZ resulted in the emergence of resistant colonies that resembled recurrent GBM clinically observed in TMZ-treated patients. However, when the parental U251N line was co-treated with TMZ and PARP-1 inhibitor ABT-888, resistant colonies failed to appear. Therefore, PARP-1 inhibition may possess the potential to maintain tumour sensitivity to TMZ as well as evade the otherwise inevitable development of resistance in GBM.</abstract><cop>New York, USA</cop><pub>Cambridge University Press</pub><doi>10.1017/cjn.2018.309</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0317-1671 |
ispartof | Canadian journal of neurological sciences, 2018-06, Vol.45 (S3), p.S4-S4 |
issn | 0317-1671 2057-0155 |
language | eng |
recordid | cdi_proquest_journals_2799854388 |
source | Cambridge University Press |
subjects | 10 MAY 2018 @ 1800-1900: 11 MAY 2018 @ 1620-1720: 12 MAY 2018 @ 1010-1035 Apoptosis Autophagy Brain cancer DNA methylation DNA repair Medical prognosis Mutation POSTER VIEWING SESSIONS Radiation |
title | 21 Inhibiting PARP-1 to restore temozolomide sensitivity and prevent resistance in glioblastoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A36%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=21%20Inhibiting%20PARP-1%20to%20restore%20temozolomide%20sensitivity%20and%20prevent%20resistance%20in%20glioblastoma&rft.jtitle=Canadian%20journal%20of%20neurological%20sciences&rft.au=Bering,%20E.%20A.&rft.date=2018-06&rft.volume=45&rft.issue=S3&rft.spage=S4&rft.epage=S4&rft.pages=S4-S4&rft.issn=0317-1671&rft.eissn=2057-0155&rft_id=info:doi/10.1017/cjn.2018.309&rft_dat=%3Cproquest_cross%3E2799854388%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1859-d2ccf1153a2993f84f5c5940cd72a8046076995b2ab1950602480228d968173f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2799854388&rft_id=info:pmid/&rft_cupid=10_1017_cjn_2018_309&rfr_iscdi=true |